secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0000950170-23-068974
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone
------------------------------------------------------------------------------

- FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Vertex set wholesale acquisition cost at $2.2 million for CASGEVY in the U.S.
- Approval triggered Vertex's $200 million milestone payment to CRISPR Therapeutics under the joint development agreement.
- This is the first-ever FDA approval of a CRISPR-based gene-editing therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/0000950170-23-068974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/crsp-20231208.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-068974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer